TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05132608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social media-based Health education program
Description: The social media-based health education program consist of 16 minute PNC video in Nepali language guided by Health Belief Model. The video provided general information on postnatal care including frequency, timing, and place providing postnatal care; danger signs of mother and newborn; different services provided at each PNC visit, and the importance of PNC visit. The researcher sent PNC videos through instant messaging (IM) software applications such as Viber, What's App, and Facebook messenger to the intervention group.
Study: NCT06635486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted cognitive-behavioral (CBT) intervention
Description: The intervention is 6-12 sessions, depending on the symptom presentation of the participant. The weekly sessions last 60 minutes and will be delivered remotely and individually via Meet or a similar platform by trained lay providers. Intervention methods include cognitive re-structuring, behavioral activation, exposure to memories and situations, problem solving, and emotional regulation.
Study: NCT05549401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(4) F1
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(4) F1
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(4) F1
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(4) F1
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(4) F1
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(4) F1
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(4) F2
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(4) F2
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(4) F2
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(4) F2
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(4) F2
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348(4) F2
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PQ
Study: NCT05961358

Intervention type: PROCEDURE
Intervention: snapshots or videos of monitor
Description: The mobile device（a phone）was used to obtain the screen image of the monitor, and the arterial blood pressure waveform is extracted by image processing technology.

Intervention type: PROCEDURE
Intervention: Pressure transducer
Description: Arterial catheter were connected to conventional pressure transducers and Flotrac-Vigileo transducers.
Study: NCT05900284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin low dose
Description: If randomized to the 500 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin high dose
Description: If randomized to the 1000 mg. Metformin arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: If randomized to the Placebo arm, a tablet will be administered orally to the study participant twice a day for the initial five days starting on the date of study enrollment. Clinical research coordinators will collect blood and urine samples from study participants in both treatment arms. The blood will be collected at Baseline, Day 1 thru 7, and at hospital discharge or Day 30, whichever occurs first. On Day 2 and Day 5, the blood will be collected at hour-based intervals of 0.5h, 1h, 2h, 4h, 8h, 12h for a pharmacokinetic profile and delivered to the University of Pittsburgh Medical Center Clinical Laboratory for analysis. The remaining blood collection tubes will be delivered to the Clinical Research Biospecimen Core laboratory to be processed, separated into microtubes, and stored at -80°. Urine samples will be collected at Baseline, Day 1, 3, and 5. The urine will be processed, separated into microtubes, and frozen at -80°.
Study: NCT05550116

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Giomer
Description: fluoride-releasing coating material containing surface reaction-type pre-reacted glass-ionomer (S-PRG) fillers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giomer
Description: fluoride-releasing coating material containing surface reaction-type pre-reacted glass-ionomer (S-PRG) fillers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giomer
Description: fluoride-releasing coating material containing surface reaction-type pre-reacted glass-ionomer (S-PRG) fillers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two composite resin sealants
Description: Unfilled composite resin sealants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two composite resin sealants
Description: Unfilled composite resin sealants
Study: NCT06280703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3938577
Description: Administered Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3938577
Description: Administered Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3938577
Description: Administered Intravenously (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered Intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered Intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered Intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered Intravenously (IV)
Study: NCT05201573

Intervention type: OTHER
Intervention: Observational
Description: This is an observational study of long term follow up data for patients who previously received the DIAM implant
Study: NCT06579664

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS
Description: Participants in active group will receive iTBS stimulation in 50-Hz triplets at 5 Hz for 600 seconds per session (2 seconds on and 8 seconds off) at 90% of their resting motor threshold to the left dorsolateral prefrontal cortex (DLPFC).Each intervention day includes 4 sessions (1800 pulses/session) of stimulation delivering a total of 7200 active pulses. This treatment protocol will be conducted 15 consecutive days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham iTBS
Description: Participants in the sham group will receive sham iTBS stimulation, which will use the same stimulation parameters, dosage, and duration as the active group, but will employ a sham coil. The sham coil is identical in appearance to the real stimulus coil and simulate the sound of a real stimulus, but do not produce a real stimulus.
Study: NCT05471960

Intervention type: OTHER
Group type: OTHER
Intervention: Natural progression over time
Description: Each subject will attend eight testing sessions (MRI scanning, two TMS-motor test visits, two TMS-prefrontal test visits, motor assessments, neuropsychological testing, and overnight sleep testing (polysomnography - PSG).

Intervention type: OTHER
Group type: OTHER
Intervention: Natural progression over time
Description: Each subject will attend eight testing sessions (MRI scanning, two TMS-motor test visits, two TMS-prefrontal test visits, motor assessments, neuropsychological testing, and overnight sleep testing (polysomnography - PSG).
Study: NCT05334498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor dual-task gait training
Description: Patients were instructed to walk either on treadmill or on the land. During walk; patients were instructed to perform five tasks. The patients performed tossing and catching the ball, rehanging loops on hoops, buttoning and unbuttoning the shirts, holding the cup in water without the spilling and receiving with returning the water. Each activity were performed for three minute and 15 minutes were provided for performing all the tasks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive dual-task gait training
Description: Patients were instructed to walk either on treadmill or on the land. During walk; patients were instructed to perform five tasks. The patients performed sharp coloring, subtraction, counting, verbal analogical reasoning and backward spelling. Each activity were performed for three minute and 15 minutes were provided for performing all the tasks
Study: NCT06109792

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported mandibular overdenture
Description: In this crossover study, the patients received overdentures with two successive different pick-up techniques for the locator retentive caps; each technique was evaluated for patient satisfaction with blue and pink retentive inserts.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported mandibular overdenture
Description: In this crossover study, the patients received overdentures with two successive different pick-up techniques for the locator retentive caps; each technique was evaluated for patient satisfaction with blue and pink retentive inserts.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported mandibular overdenture
Description: In this crossover study, the patients received overdentures with two successive different pick-up techniques for the locator retentive caps; each technique was evaluated for patient satisfaction with blue and pink retentive inserts.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported mandibular overdenture
Description: In this crossover study, the patients received overdentures with two successive different pick-up techniques for the locator retentive caps; each technique was evaluated for patient satisfaction with blue and pink retentive inserts.
Study: NCT04701151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette Guerin
Description: The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette Guerin
Description: The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.
Study: NCT05563103

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Daily acute intermittent hypoxia
Description: Each participant will be exposed to 8 sessions of daily acute intermittent hypoxia via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily acute intermittent hypoxia
Description: Each participant will be exposed to 8 sessions of daily acute intermittent hypoxia via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Room air (SHAM)
Description: Each participant will be exposed to 8 sessions of daily room air via air generators over the span of two weeks. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking + tSTIM
Description: Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Walking + tSTIM
Description: Individuals will participate in 45 minutes of gait training while having transcutaneous spinal cord stimulation. Stimulation intensity will be 80% involuntary motor threshold.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Walking + Sham transcutaneous spinal stimulation (tSHAM)
Description: Individuals will participate in 45 minutes of gait training while having SHAM transcutaneous spinal cord stimulation. The stimulation will briefly increase to 80% involuntary motor threshold and then brought down to 0 within 30 seconds.
Study: NCT05042336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab/lenvatinib combined with TACE
Description: Lenvatinib 4mg qd body weight≤60,8mg；body weight\>60,12mg~Camrelizumab 200mg q2w/q3w
Study: NCT04944602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYN008
Description: injection of 300 mg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab for injection
Description: injection of 300 mg
Study: NCT05349903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice flour
Description: Rice flour made into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternanoligosaccharide 15
Description: Alternanoligosaccharide 15 incorporated into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin incorporated into rice porridge will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waxy potato starch
Description: Retrograded waxy potato starch made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waxy potato starch + epigallocatechin gallate (EGCG)
Description: A combination of retrograded waxy potato starch and EGCG made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chickpea flour + epigallocatechin gallate (EGCG)
Description: A combination of chickpea flour and EGCG made into porridge meal will be tested for postprandial glycemic response, gut hormone levels, gastric emptying rate, appetitive response, and fermentability.
Study: NCT05317156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold vapor
Description: Before surgery, the socio-demographic data of the patients will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat, cough, hoarseness, and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th,12th, and 24th hours after the cold vapor application in the postoperative service. In addition, the comfort levels of the patients will be evaluated at the 24th postoperative hour.
Study: NCT05047367

Intervention type: BEHAVIORAL
Intervention: cross-sectional survey study
Description: Beck Depression Scale, Beck Anxiety Scale for psychological evaluation, Visual Analogue Scale and PainDETECT Questionnaire for pain, Pittsburgh Sleep Quality Scale and Epworth Sleepiness Scale for sleep quality
Study: NCT05968001

Intervention type: DRUG
Intervention: Obinutuzumab
Description: obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.

Intervention type: DRUG
Intervention: Obinutuzumab
Description: obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.
Study: NCT04911790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection
Study: NCT05485168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential Variety
Description: 3 different foods served in 3 successive courses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential Variety
Description: 3 different foods served in 3 successive courses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-Food
Description: 1 food served in 3 successive courses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-Food
Description: 1 food served in 3 successive courses
Study: NCT05485168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small Portion
Description: Small meal portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small Portion
Description: Small meal portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Portion
Description: Large meal portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Portion
Description: Large meal portion size
Study: NCT05126381

Intervention type: BEHAVIORAL
Intervention: Smoking
Description: The Study contains patients who are allowed to smoke

Intervention type: BEHAVIORAL
Intervention: Smoking
Description: The Study contains patients who are allowed to smoke

Intervention type: BEHAVIORAL
Intervention: non-somking
Description: The Study contains patients who are not allowed to smoke

Intervention type: BEHAVIORAL
Intervention: non-somking
Description: The Study contains patients who are not allowed to smoke
Study: NCT04995978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg
Description: Subjects will self-administer a 30 mg pioglitazone oral tablet daily for 6 months.~For patient taking a diabetic regimen of gemfibrozil, the dose will be 15 mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: Subjects will self-administer an oral placebo tablet containing cellulose daily for 6 months.
Study: NCT04822688

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of tissue and blood samples
Study: NCT05753774

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT
Description: FMT is a technique in which intestinal microbiota are transferred from a healthy screened donor to a patient, with the goal being to introduce or restore a stable microbial community in the gut. FMT was given 1-3courses, 3-6 times per courses

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Conventional drugs
Description: Conventional drugs include probiotics and omeprazole, and cyproheptadine and moxapride
Study: NCT04951050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapamycin target eluting stent
Description: Rapamycin target eluting stent
Study: NCT05170555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-PSMA. Tracer doses of 68Ga- PSMA will be used to image lesions of Renal Cell Carcinoma by PET/CT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
Description: Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.